FR20C1022I2 - DOSAGE OF AN S1P RECEPTOR AGONIST - Google Patents

DOSAGE OF AN S1P RECEPTOR AGONIST

Info

Publication number: FR20C1022I2
Authority: FR; France
Prior art keywords: dosage; receptor agonist; agonist; receptor
Prior art date: 2008-12-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR20C1022C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2020-06-18

Publication date

2021-06-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41435196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1022(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-06-18 Application filed by Novartis AG filed Critical Novartis AG

2020-07-31 Publication of FR20C1022I1 publication Critical patent/FR20C1022I1/fr

2021-06-11 Application granted granted Critical

2021-06-11 Publication of FR20C1022I2 publication Critical patent/FR20C1022I2/en

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Transplantation (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Pyrrole Compounds (AREA)

FR20C1022C 2008-12-22 2020-06-18 DOSAGE OF AN S1P RECEPTOR AGONIST Active FR20C1022I2 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US13967308P	2008-12-22	2008-12-22
EP09167209		2009-08-04
EP09793546.4A EP2379069B1 (en)	2008-12-22	2009-12-21	Dosage regimen of an s1p receptor agonist
PCT/EP2009/067618 WO2010072703A1 (en)	2008-12-22	2009-12-21	Dosage regimen of an s1p receptor agonist

Publications (2)

Publication Number	Publication Date
FR20C1022I1 FR20C1022I1 (en)	2020-07-31
FR20C1022I2 true FR20C1022I2 (en)	2021-06-11

Family

ID=41435196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR20C1022C Active FR20C1022I2 (en)	2008-12-22	2020-06-18	DOSAGE OF AN S1P RECEPTOR AGONIST

Country Status (35)

Country	Link
US (2)	US8492441B2 (en)
EP (1)	EP2379069B1 (en)
JP (2)	JP5657565B2 (en)
KR (1)	KR101660555B1 (en)
CN (2)	CN105213372A (en)
AR (1)	AR074825A1 (en)
AU (1)	AU2009331582B2 (en)
BR (1)	BRPI0923213A2 (en)
CA (3)	CA2981830A1 (en)
CY (2)	CY1116321T1 (en)
DK (1)	DK2379069T3 (en)
ES (1)	ES2538413T3 (en)
FR (1)	FR20C1022I2 (en)
HK (1)	HK1159524A1 (en)
HR (1)	HRP20150567T1 (en)
HU (2)	HUE026400T2 (en)
IL (2)	IL294658A (en)
JO (1)	JO3044B1 (en)
LT (1)	LTC2379069I2 (en)
LU (1)	LUC00160I2 (en)
MA (1)	MA32907B1 (en)
MX (2)	MX2011006625A (en)
NL (1)	NL301046I2 (en)
NO (1)	NO2020017I1 (en)
NZ (1)	NZ593427A (en)
PL (1)	PL2379069T3 (en)
PT (1)	PT2379069E (en)
RU (1)	RU2561681C2 (en)
SG (1)	SG171888A1 (en)
SI (1)	SI2379069T1 (en)
TN (1)	TN2011000281A1 (en)
TW (1)	TWI472327B (en)
UY (1)	UY32350A (en)
WO (1)	WO2010072703A1 (en)
ZA (1)	ZA201104102B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101718639B1 (en)	2008-03-17	2017-03-21	액테리온 파마슈티칼 리미티드	Dosing Regimen for a Selective S1P1 Receptor Agonist
PL2307007T3 (en) *	2008-07-23	2015-03-31	Novartis Ag	Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
SI2379067T1 (en) *	2008-12-22	2016-01-29	Novartis Ag	Dosage regimen for fingolimod for the treatment of multiple sclerosis
CN103221391B (en)	2010-01-27	2018-07-06	艾尼纳制药公司	(R) preparation method of -2- (7- (4- cyclopenta -3- (trifluoromethyl) benzyls oxygroup) -1,2,3,4- tetrahydro cyclopentyl diene simultaneouslies [b] indol-3-yl) acetic acid and its salt
AU2011249789B2 (en) *	2010-05-06	2015-03-19	Novartis Ag	Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) *	2010-11-23	2012-05-23	Almirall, S.A.	S1P1 receptor agonists for use in the treatment of multiple sclerosis
UA114283C2 (en)	2011-01-07	2017-05-25	Новартіс Аг	COMPOSITIONS OF IMMUNOSUPRESSANTS
WO2012095853A1 (en)	2011-01-10	2012-07-19	Novartis Pharma Ag	Modified release formulations comprising sip receptor modulators
EP2768494A1 (en) *	2011-10-21	2014-08-27	Novartis AG	Dosage regimen for an s1p receptor modulator or agonist
DK2885266T3 (en)	2012-08-17	2020-06-08	Actelion Pharmaceuticals Ltd	METHOD FOR PREPARING (2Z, 5Z) -5- (3-CHLOR-4 - ((R) -2,3-DIHYDROXYPROPOXY) BENZYLIDE) -2- (PROPYLIMINO) -3- (O-TOLYL) THIAZOLIDIN-4- ON AND INTERMEDIATE PRODUCTS USED IN THE PROCEDURE
JP6240746B2 (en)	2013-04-04	2017-11-29	ノバルティスアーゲー	Identification of patient response to S1P receptor modulator administration
HUE054245T2 (en) *	2014-04-10	2021-08-30	Novartis Ag	Immunosuppressant formulation
CN106456552A (en) *	2014-04-10	2017-02-22	诺华股份有限公司	S1P modulator immediate release dosage regimen
TW201625242A (en)	2014-12-11	2016-07-16	艾克泰聯製藥有限公司	Dosing regimen for selective S1P receptor agonists
NZ734220A (en) *	2015-01-06	2022-01-28	Arena Pharm Inc	Methods of treating conditions related to the s1p1 receptor
US20180042895A1 (en) *	2015-02-26	2018-02-15	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
MA42807A (en)	2015-06-22	2018-07-25	Arena Pharm Inc	SALT L-ARGININE CRYSTALLINE ACID (R) -2- (7- (4-CYCLOPENTYL-3- (TRIFLUOROMETHYL) BENZYLOXY) -1,2,3,4-TETRAHYDROCYCLO-PENTA [B] INDOL-3-YL) ACETIC (COMPOUND 1) FOR USE IN CONDITIONS ASSOCIATED WITH THE S1P1 RECEIVER
KR20190113955A (en)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	Compounds and Methods for the Treatment of Inflammatory Bowel Disease With Extra-Intestinal Symptoms
CA3053418A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11046646B2 (en)	2017-08-09	2021-06-29	Bristol-Myers Squibb Company	Alkylphenyl compounds
US11059784B2 (en)	2017-08-09	2021-07-13	Bristol-Myers Squibb Company	Oxime ether compounds
CA3073910A1 (en) *	2017-09-29	2019-04-04	Novartis Ag	Dosing regimen of siponimod
KR20200062240A (en) *	2017-09-29	2020-06-03	노파르티스 아게	Administration of siphonimod
AU2019280822A1 (en)	2018-06-06	2021-01-07	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
AU2020372647A1 (en)	2019-10-31	2022-06-16	Idorsia Pharmaceuticals Ltd	Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021158848A1 (en) *	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Dosage regimen of an s1p receptor agonist
WO2021158838A1 (en)	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Dosage regimen of an s1p receptor modulator
MX2023009249A (en)	2021-02-08	2023-10-23	Bausch Health Ireland Ltd	Amiselimod for preventing, treating, or ameliorating ulcerative colitis.
EP4212156A1 (en)	2022-01-13	2023-07-19	Abivax	Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1176819A (en) *	1997-09-03	1998-03-25	王树生	Sobering beverage and method for preparing same
BR0311173A (en)	2002-05-16	2005-03-15	Novartis Ag	Use of edg receptor binding agents in cancer
MY150088A (en) *	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
WO2005000833A1 (en)	2003-05-19	2005-01-06	Irm, Llc	Immunosuppressant compounds and compositions
CN1874767A (en) *	2003-10-29	2006-12-06	惠氏公司	Sustained release pharmaceutical compositions comprising APLINDORE and derivatives thereof
CA2548790A1 (en)	2003-12-17	2005-06-30	Dainippon Sumitomo Pharma Co., Ltd.	Medicinal compositions and combinations
UA74941C2 (en)	2004-04-26	2006-02-15	Fos Internat S A	A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en)	2004-05-05	2005-12-01	Adler, Richard, S.	Systems and methods for protecting ship from attack on the surface or under water
SG158096A1 (en) *	2004-11-29	2010-01-29	Novartis Ag	Dosage regimen of an s1p receptor agonist
KR20080047538A (en) *	2005-09-09	2008-05-29	라보팜 인코포레이트	Sustained drug release composition
WO2008072056A1 (en) *	2006-12-14	2008-06-19	Pfizer Limited	Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (en) *	2007-04-23	2008-11-13	Grünenthal GmbH	Tapentadol for the treatment of pain in osteoarthritis
PL2465492T3 (en) *	2007-10-12	2015-11-30	Novartis Ag	Compositions comprising sphingosine I phosphate (sip) receptor modulators

2009
- 2009-12-21 BR BRPI0923213A patent/BRPI0923213A2/en not_active IP Right Cessation
- 2009-12-21 KR KR1020117017072A patent/KR101660555B1/en active IP Right Grant
- 2009-12-21 AR ARP090105009A patent/AR074825A1/en unknown
- 2009-12-21 WO PCT/EP2009/067618 patent/WO2010072703A1/en active Application Filing
- 2009-12-21 HU HUE09793546A patent/HUE026400T2/en unknown
- 2009-12-21 CA CA2981830A patent/CA2981830A1/en not_active Abandoned
- 2009-12-21 TW TW98143961A patent/TWI472327B/en active
- 2009-12-21 IL IL294658A patent/IL294658A/en unknown
- 2009-12-21 DK DK09793546.4T patent/DK2379069T3/en active
- 2009-12-21 SI SI200931199T patent/SI2379069T1/en unknown
- 2009-12-21 CN CN201510541635.7A patent/CN105213372A/en active Pending
- 2009-12-21 RU RU2011129856/15A patent/RU2561681C2/en active
- 2009-12-21 MX MX2011006625A patent/MX2011006625A/en active IP Right Grant
- 2009-12-21 JP JP2011541496A patent/JP5657565B2/en active Active
- 2009-12-21 PL PL09793546T patent/PL2379069T3/en unknown
- 2009-12-21 AU AU2009331582A patent/AU2009331582B2/en active Active
- 2009-12-21 CN CN2009801519427A patent/CN102264363A/en active Pending
- 2009-12-21 CA CA2747992A patent/CA2747992C/en active Active
- 2009-12-21 SG SG2011039765A patent/SG171888A1/en unknown
- 2009-12-21 NZ NZ593427A patent/NZ593427A/en not_active IP Right Cessation
- 2009-12-21 MX MX2015011590A patent/MX367667B/en unknown
- 2009-12-21 CA CA3105857A patent/CA3105857C/en active Active
- 2009-12-21 UY UY0001032350A patent/UY32350A/en not_active Application Discontinuation
- 2009-12-21 EP EP09793546.4A patent/EP2379069B1/en active Active
- 2009-12-21 ES ES09793546.4T patent/ES2538413T3/en active Active
- 2009-12-21 PT PT97935464T patent/PT2379069E/en unknown
- 2009-12-21 JO JOP/2009/0495A patent/JO3044B1/en active
- 2009-12-22 US US12/655,049 patent/US8492441B2/en active Active
2011
- 2011-05-31 TN TN2011000281A patent/TN2011000281A1/en unknown
- 2011-06-02 IL IL21334711A patent/IL213347B/en active IP Right Grant
- 2011-06-02 ZA ZA2011/04102A patent/ZA201104102B/en unknown
- 2011-06-17 MA MA33953A patent/MA32907B1/en unknown
2012
- 2012-01-10 HK HK12100257.4A patent/HK1159524A1/en unknown
2013
- 2013-06-18 US US13/920,406 patent/US20130281712A1/en active Pending
2014
- 2014-09-19 JP JP2014191541A patent/JP5941110B2/en active Active
2015
- 2015-05-27 CY CY20151100469T patent/CY1116321T1/en unknown
- 2015-05-27 HR HRP20150567TT patent/HRP20150567T1/en unknown
2020
- 2020-06-16 NL NL301046C patent/NL301046I2/en unknown
- 2020-06-17 HU HUS2000017C patent/HUS2000017I1/en unknown
- 2020-06-17 NO NO2020017C patent/NO2020017I1/en unknown
- 2020-06-18 LU LU00160C patent/LUC00160I2/fr unknown
- 2020-06-18 FR FR20C1022C patent/FR20C1022I2/en active Active
- 2020-06-19 CY CY2020014C patent/CY2020014I2/en unknown
- 2020-06-23 LT LTPA2020513C patent/LTC2379069I2/en unknown

Also Published As

Publication number	Publication date
IL213347A0 (en)	2011-07-31
FR20C1022I1 (en)	2020-07-31
NZ593427A (en)	2013-11-29
HUS2000017I1 (en)	2020-07-28
MA32907B1 (en)	2011-12-01
LTC2379069I2 (en)	2022-05-25
PT2379069E (en)	2015-07-03
HK1159524A1 (en)	2012-08-03
NO2020017I1 (en)	2020-06-17
ES2538413T3 (en)	2015-06-19
CN102264363A (en)	2011-11-30
AR074825A1 (en)	2011-02-16
SI2379069T1 (en)	2015-07-31
TN2011000281A1 (en)	2012-12-17
CA3105857C (en)	2023-08-01
LTPA2020513I1 (en)	2020-07-27
EP2379069A1 (en)	2011-10-26
JP2015038097A (en)	2015-02-26
JP2012513378A (en)	2012-06-14
UY32350A (en)	2010-04-30
PL2379069T3 (en)	2015-08-31
IL294658A (en)	2022-09-01
RU2561681C2 (en)	2015-08-27
SG171888A1 (en)	2011-07-28
EP2379069B1 (en)	2015-03-04
AU2009331582A1 (en)	2011-06-30
US20110039818A1 (en)	2011-02-17
US8492441B2 (en)	2013-07-23
TW201028147A (en)	2010-08-01
NL301046I2 (en)	2020-07-29
BRPI0923213A2 (en)	2016-01-26
WO2010072703A1 (en)	2010-07-01
MX367667B (en)	2019-08-30
ZA201104102B (en)	2012-02-29
KR20110106399A (en)	2011-09-28
US20130281712A1 (en)	2013-10-24
IL213347B (en)	2019-11-28
DK2379069T3 (en)	2015-06-08
LUC00160I1 (en)	2020-06-19
CN105213372A (en)	2016-01-06
LUC00160I2 (en)	2021-07-06
CY2020014I1 (en)	2020-11-25
KR101660555B1 (en)	2016-09-27
CA2747992C (en)	2017-11-07
CA3105857A1 (en)	2010-07-01
HUE026400T2 (en)	2016-06-28
JO3044B1 (en)	2016-09-05
CY2020014I2 (en)	2020-11-25
MX2011006625A (en)	2011-09-28
TWI472327B (en)	2015-02-11
CA2981830A1 (en)	2010-07-01
HRP20150567T1 (en)	2015-08-14
CA2747992A1 (en)	2010-07-01
CY1116321T1 (en)	2017-02-08
JP5657565B2 (en)	2015-01-21
JP5941110B2 (en)	2016-06-29
NL301046I1 (en)	2020-06-17
AU2009331582B2 (en)	2014-03-13

Publication	Publication Date	Title
FR20C1022I2 (en)	2021-06-11	DOSAGE OF AN S1P RECEPTOR AGONIST
CY2020036I1 (en)	2021-03-12	DOSAGE FORMS FOR AN S1P RECEPTOR AGENT
MA29034B1 (en)	2007-11-01	DOSAGE OF S1P RECEPTOR AGONIST
FR22C1044I1 (en)	2022-09-30	CGRP RECEPTOR ANTAGONISTS
HK1244669A1 (en)	2018-08-17	Composition for delivering long-acting muscarinic antagonist and long-acting β2 adrenergic receptor agonist through the lungs and related methods and systems
EP2150115A4 (en)	2011-08-03	RECEPTOR ANTAGONISTS OF CYCLOPROPYLPYRROLIDINE OREXINE
KR101522157B9 (en)	2024-07-31	Dosage of CMT inhibitors
DK2421849T3 (en)	2013-07-01	Diamide compounds with muscarinic receptor antagonist and beta2-adrenoreceptor agonist activity
DK2252581T3 (en)	2012-07-16	CAPE-SELECTIVE OPIOID RECEPTOR ANTAGONIST
HK1246811A1 (en)	2018-09-14	Mu opioid receptor agonist analogs of the endomorphins
EP2427430A4 (en)	2013-01-09	ANTAGONIST COMPOUNDS OF 5-OXO-SUMMER RECEPTORS
EP2773352A4 (en)	2015-12-16	4-ARYLPIPERAZINE 1-SUBSTITUTED AS ANTAGONIST OF OPIOID RECEPTOR KAPPA
EP2365748A4 (en)	2012-05-02	IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS
EP2539706A4 (en)	2013-07-31	ARYLPIPERAZONE ANTAGONISTS OF OPIOID RECEPTORS
EP2578569A4 (en)	2014-01-15	HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST
EP2341919A4 (en)	2012-05-30	CGRP RECEPTOR ANTAGONISTS
EP2089019A4 (en)	2011-05-04	POLYMORPHS OF AN ANTAGONIST OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
EP2339919A4 (en)	2012-02-29	ANTAGONISTS OF CGRP RECEPTORS BASED ON BICYCLIC DIHYDROIMIDAZOLONE
BRPI1014548A2 (en)	2015-08-25	Methods of Administration of Thrombopoietin Agonist Compounds
TH0901005765A (en)	2016-05-10	Size specifications for S1P Receptor Agonist
UA17747S (en)	2008-11-10	DEVICE FOR INSPECTION OF PIPELINES "GNOM-100 D"